Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04958239
Title	A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Boehringer Ingelheim
Indications	pancreatic adenocarcinoma colorectal cancer bladder urothelial carcinoma stomach cancer esophagus squamous cell carcinoma lung non-small cell carcinoma cervical squamous cell carcinoma ovarian carcinoma laryngeal squamous cell carcinoma skin melanoma hypopharynx cancer esophagus adenocarcinoma malignant pleural mesothelioma oral squamous cell carcinoma head and neck squamous cell carcinoma triple-receptor negative breast cancer skin squamous cell carcinoma hepatocellular carcinoma oropharynx cancer
Therapies	BI 765179 + Ezabenlimab BI 765179
Age Groups:	adult \| senior
Covered Countries	USA \| NLD \| ITA \| ISR \| FRA \| ESP \| DEU \| CZE \| BRA \| BEL \| AUS